| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND: Vitamin D has an immunomodulatory role but the effect of therapeutic vitamin D supplementation in SARS-CoV-2 infection is not known AIM: Effect of high dose, oral cholecalciferol supplementation on SARS-CoV-2 viral clearance DESIGN: Randomised, placebo-controlled PARTICIPANTS: Asymptomatic or mildly symptomatic SARS-CoV-2 RNA positive vitamin D deficient (25(OH)D50 ng/ml (intervention group) or placebo (control group) Patients requiring invasive ventilation or with significant comorbidities were excluded 25(OH)D levels were assessed at day 7, and cholecalciferol supplementation was continued for those with 25(OH)D 50 ng/ml by day-7 and another two by day-14 [day-14 25(OH)D levels 51 7 (48 9 to 59 5) ng/ml and 15 2 (12 7 to 19 5) ng/ml (p<0 001) in intervention and control group, respectively] 10 (62 5%) participants in the intervention group and 5 (20 8%) participants in the control arm (p<0 018) became SARS-CoV-2 RNA negative Fibrinogen levels significantly decreased with cholecalciferol supplementation (intergroup difference 0 70 ng/ml;P=0 007) unlike other inflammatory biomarkers CONCLUSION: Greater proportion of vitamin D-deficient individuals with SARS-CoV-2 infection turned SARS-CoV-2 RNA negative with a significant decrease in fibrinogen on high-dose cholecalciferol supplementation TRIAL REGISTER NUMBER: NCT04459247
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study)
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}